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Perioperative asymptomatic cardiac damage after
endovascular abdominal aneurysm repair is
associated with poor long-term outcome
Tamara A. Winkel, MD,a Olaf Schouten, MD,a Jan-Peter van Kuijk, MD,b Hence J. M. Verhagen, MD,a
Jeroen J. Bax, MD,c and Don Poldermans, MD,b Rotterdam and Leiden, The Netherlands
Background: Endovascular abdominal aortic aneurysm (AAA) repair (EVAR) is associated with a decreased incidence of
perioperative cardiac complications compared with open repair. However, EVAR is not associated with long-term
survival benefit. This study assessed the effect of perioperative asymptomatic cardiac damage after EVAR on long-term
prognosis.
Methods: In 220 patients undergoing elective EVAR, routine sampling for levels of cardiac troponin T and electrocardi-
ography (ECG) were performed on days 1, 3, and 7 during the patient’s hospital stay. Elevated cardiac troponin T was
defined as serum concentrations >0.01 ng/mL. Asymptomatic cardiac damage was defined as cardiac troponin T release
without symptoms or ECG changes. The median follow-up was 2.9 years. Survival status was obtained by contacting the
Office of Civil Registry.
Results: Release of cardiac troponin T (median, 0.08 ng/mL) occurred in 24 of 220 patients, of whom 20 (83%) were
asymptomatic and without ECG changes. Patients with asymptomatic cardiac damage had a mortality rate of 85% after
2.9 years vs 51% for patients without perioperative cardiac damage (P < .001). Also after adjustment for clinical risk
factors and medication use applying multivariate Cox regression analysis, asymptomatic cardiac damage was associated
with a 2.3-fold increased risk for death (95% confidence interval, 1.1-5.1). Statin use was associated with a reduced
long-term risk for death (hazard ratio, 0.5; 95% confidence interval, 0.3-0.9).
Conclusion: Asymptomatic cardiac damage in patients undergoing EVAR is associated with poor long-term outcome.
Routine perioperative cardiac screening after EVAR might be warranted. (J Vasc Surg 2009;50:749-54.)Endovascular abdominal aneurysm (AAA) repair (EVAR)
is associated with fewer perioperative cardiac complications
compared with open AAA repair. Although symptomatic
and asymptomatic cardiac damage occurs in up to 25% of
patients undergoing open AAA repair, the incidence of
symptomatic and asymptomatic cardiac damage in EVAR is
about 10%, even in those at high cardiac risk.1-3
Despite this perioperative cardiac advantage of EVAR,
the early benefits of EVAR dissipate 2 years, as has been
shown in the Dutch Randomised Endovascular Aneurysm
Management (DREAM) and Comparison of Endovascular
Aneurysm Repair with Open Repair in Patients with Ab-
dominal Aortic Aneurysm (EVAR-1) trials.4,5 Although
aneurysm-related survival in DREAM and EVAR-1 was
better in patients treated with endovascular techniques,
all-cause mortality was similar in both groups. Cardiac-frail
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doi:10.1016/j.jvs.2009.04.069patients are less likely to survive the stress of open repair
than the relatively safe endovascular repair. Consequently,
several studies have suggested that long-term outcome
after successful AAA repair is related primarily to the pres-
ence and extent of underlying coronary artery disease and
not to treatment modality.6,7
If patients are screened rigorously after EVAR, how-
ever, a substantial proportion will have asymptomatic car-
diac damage as assessed by cardiac tronopin T measure-
ments,1,2 which is a sensitive and specific marker for
myocardial injury.8 However, the effect of elevations of
cardiac troponin T, without clinical evidence of myocardial
ischemia and persistent electrocardiographic (ECG) abnor-
malities, is unknown.
If asymptomatic cardiac troponin T release after endo-
vascular treatment is associated with poor long-term out-
come, it might be used to identify those patients who will
benefit from aggressive follow-up and medical treatment
after EVAR. Therefore, we planned the current study to
assess the prognostic value of asymptomatic cardiac tropo-
nin T release in patients undergoing EVAR.
METHODS
Patients. The study population consisted of 220 pa-
tients undergoing elective EVAR from January 2003 to
November 2008. These patients were identified in a pro-
spectively maintained database of all patients undergoing
vascular surgery at Erasmus Medical Center, Rotterdam,
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mus Medical Center approved the study.
Before surgery, a detailed cardiac history was obtained,
and patients were screened for hypertension (blood pres-
sure 140/90 mm Hg, or medical therapy to control
hypertension) and diabetes mellitus (fasting glucose level
7.0 mmol/L, or medication to control diabetes). The
presence of coronary artery disease was indicated by a
previous myocardial infarction, previous coronary interven-
tion, or present stable angina pectoris. Other cardiovascular
risk factors documented were a history of cerebrovascular
accident or transient ischemic attack, age 70 years,
chronic heart failure, and chronic obstructive pulmonary
disease (defined as a forced expiratory volume in 1 second
70% of age and gender predictive value, or medication
use). Preoperative serum creatinine values were routinely
obtained.
The Modification of Diet in Renal Disease formula
[186 (serum creatinine)–1.154 (age)–0.203 (0.742 if
female)  (1.212 if African American)] was used to estimate
the glomerular filtration rate (eGFR). Patients were catego-
rized as having no renal impairment (eGFR 90 mL/min/
1.73 m2), mild renal impairment (60 to 90 mL/min/1.73
m2), moderate renal impairment (30 to 60 mL/min/1.73
m2), and severe renal impairment (30 mL/min/1.73 m2).
Additional cardiac stress testing. Preoperative stress
testing at our institution is done according to the number
of cardiac risk factors identified at preoperative screening.
Patients without cardiac risk factors usually do not undergo
additional cardiac stress testing. As is shown in the Dutch
Echocardiographic Cardiac Risk Evaluation (DECREASE
II) trial, patients with one or two factors also do not need
additional cardiac stress testing.9 Patients with three or
more risk factors all undergo additional testing. Some
patients included in the current study underwent EVAR
before the DECREASE II trial was completed; thus, some
patients with one or two risk factors also underwent addi-
tional cardiac stress testing. Because we did not have
stress test results for all patients, we did not perform an
analysis between preoperative stress testing and postop-
erative outcome.
Troponin measurement. Troponin T levels are rou-
tinely measured at our institution in patients undergoing
major vascular surgery on postoperative days 1, 3, and 7 of
the patient’s hospital stay, and whenever clinically indicated
by ECG changes consistent with myocardial ischemia or
infarction. ECGs are routinely recorded preoperatively and
on days 1, 3, and 7 of the patient’s hospital stay, and at 30
days after surgery. Troponin T levels were measured by
using a whole blood rapid test (TropT v2; Roche Diagnos-
tics, Mannheim, Germany). Only patients with asymptom-
atic cardiac troponin T release (ie, without ischemic symp-
toms or new ECG abnormalities) were included in the
current study.
End point. In January 2009 a follow-up was per-
formed of all patients who survived major vascular surgery
for at least 30 days. The primary end point was death from
all causes to avoid misclassification among cardiac, arrhyth-mic, and noncardiac deaths. Information about vital status
was requested from the Office of Civil Registry.
Statistical analysis. The Fisher exact test was used to
compare dichotomous variables, and the Kruskal-Wallis
test was used to compare continuous variables. The Kaplan-
Meier method was used to evaluate the prognostic value of
asymptomatic troponin release with respect to survival.
Differences in survival curves were compared by the log-
rank test.
Univariable Cox proportional hazard regression mod-
els were used to assess the independent association between
troponin release, baseline clinical characteristics, and all-
cause mortality. To avoid model over-fitting, we applied a
clinical risk model used in the DECREASE studies.9,10 In
this model, 1 point is assigned for the following risk factors:
age70 years, myocardial infarction, angina pectoris, heart
failure, diabetes mellitus, renal dysfunction, and history of
cerebrovascular accident or transient ischemic attack. Pa-
tients with no risk factors are considered at low cardiac
risk, those with 1 or 2 risk factors are at intermediate
cardiac risk, and those with 3 risk factors are at high
cardiac risk. Multivariable regression models were con-
structed by backward stepwise deletion of the least sig-
nificant characteristics.
Hazard ratios (HR) and corresponding 95% confidence
intervals (CI) are reported; continuous data are reported
with the interquartile range (IQR). For all tests, a value of
P  .05 was considered significant. All analyses were per-
formed using SPSS 15.0 software (SPSS Inc, Chicago, Ill).
RESULTS
Patient characteristics. The study included 220 pa-
tients (88% men) undergoing EVAR. Their mean age was
72.9  7.4 years. General anesthesia was used in 102
patients (47%). According to the cardiac risk score, the
cardiac risk was low in 14%, intermediate in 60%, and high
in 26%. Troponin T release was documented in 24 patients
(10.9%) 30 days after surgery. Four patients (17%) had
symptomatic troponin T release or ECG changes, or both,
and 20 (83%) had asymptomatic troponin T release without
ECG changes. Baseline differences between patients with
and without asymptomatic troponin T release are reported
in Table I. Patients who experienced asymptomatic tropo-
nin T release were more likely to have preoperative renal
dysfunction; 11 of 20 (55%) of patients with postoperative
asymptomatic troponin T release had an estimated GFR
60 mL/min/1.73 m2 compared with 40 of 196 (20%)
without postoperative troponin T release (P  .01). Post-
operatively, 22 patients were admitted to the postanesthe-
sia care unit or intensive care unit (ICU). Only two patients
required an ICU stay longer than 1 day.
Long-term prognosis of patients with asymptom-
atic cardiac damage. The median follow-up was 2.9 years
(IQR, 0.9-4.3 years), during which 46 patients (21%) died.
Asymptomatic troponin T release was significantly associ-
ated with poor long-term survival in patients undergoing
EVAR (Fig 1). In univariate analysis, patients with asymp-
tomatic troponin T release had a 3.6-fold increased risk
ischem
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ables that were associated with poor long-term outcome
included a history of ischemic heart disease (HR, 1.6; 95%
CI, 0.9-2.9), heart failure (HR, 2.4; 95% CI, 1.1-5.2),
renal failure (HR, 2.3; 95% CI, 1.1-4.8), and age70 years
(HR, 2.1; 95% CI, 1.1-4.3). Importantly, also in multivar-
iate analysis, asymptomatic cardiac troponin release was still
associated with a 2.3-fold (95% CI, 1.1-5.1) increased risk
for all-cause mortality during a median follow-up of 2.9
years (Table II).
Long-term prognosis of patients with asymptom-
atic cardiac damage and renal dysfunction. A recurring
Table I. Baseline clinical characteristics
Variable All patients
No. (%) or mean  SD (N  216)
Male 190 (88)
Age, y 73  7.4
Myocardial infarction 74 (34)
Angina 53 (25)
Heart failure 19 (9)
TIA or CVA 30 (14)
Diabetes 26 (12)
Renal dysfunction 23 (11)
Hypertension 122 (57)
COPD 59 (27)
Previous CABG or PCI 40 (19)







CABG, Coronary artery bypass grafting; COPD, chronic obstructive pulmon
percutaneous coronary intervention; SD, standard deviation; TIA, transient















Fig 1. Long-term survival of patients without perioperative tro-
ponin release is compared with patients with asymptomatic tropo-
nin release.discussion is whether asymptomatic cardiac troponin Trelease in patients with renal dysfunction has any clinical
relevance. A separate analysis was done of the 51 patients
who had an eGFR60mL/min/1.73m2; of these, 11 had
asymptomatic cardiac troponin release that was associated
with a 3.0-fold (95% CI, 1.2-7.5) increased risk for long-
term mortality (Fig 2). Multivariate analysis also docu-
mented a significant 2.8-fold (95% CI, 1.1-7.3) in-
creased risk for death when adjusted for the presence of
ischemic heart disease, age 70 years, and congestive
heart failure.
Effect of statin therapy on long-term outcome. At
the time of hospital discharge, 41% of patients were not
receiving statin therapy. During follow-up, use of statins at
hospital discharge was associated with a decrease in all-
cause mortality compared with nonuse (HR, 0.52; 95% CI,
0.29-0.94, Fig 3). After adjustment for clinical baseline
characteristics and perioperative troponin release, statin use
was also associated with improved outcome (HR, 0.47;
Troponin Troponin–
P(n  20) (n  196)
18 (90) 172 (88) .77
77  6.6 73  7.4 .01
6 (30) 68 (35) .81
6 (30) 47 (24) .55
3 (15) 16 (8) .30
5 (25) 25 (13) .13
2 (10) 24 (12) .77
5 (25) 18 (9) .03
10 (50) 112 (57) .54
6 (30) 53 (27) .78
1 (5) 39 (20) .13
15 (75) 172 (88) .11
9 (45) 116 (59) .22
.01
4 (20) 6 (3)
7 (35) 34 (17)
6 (30) 104 (53)
3 (15) 52 (27)
sease; CVA, cerebrovascular accident; GFR, glomerular filtration rate; PCI,
ic attack.
Table II. Multivariate Cox regression analysis for
all-cause mortalitya
Variable HR 95% CI P
Peri-op troponin release 2.33 1.07-5.07 .03
Age, per year increase 1.05 1.01-1.10 .02
Ischemic heart disease 1.88 0.99-3.55 .05
GFRb 60 mL/min/1.73 m2 1.81 0.92-3.56 .09
Statin use 0.47 0.25-0.90 .02
CI, Confidence interval; GFR, glomerular filtration rate; HR, hazard ratio.
aAdjusted for age, gender, diabetes, stroke, chronic obstructive pulmonary
disease, hypertension.
bEstimated using the Modification of Diet in Renal Disease formula.ary di95% CI, 0.25-0.90).
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The current study shows a strong association between
perioperative asymptomatic cardiac troponin T release and
poor long-term outcome after EVAR.Despite the relatively
low surgical stress of EVAR, approximately 10% of patients
sustain asymptomatic myocardial damage that will not be
detected without routine postoperative cardiac troponin T
measurements.
The perioperative benefits of EVAR are widely ac-
cepted, but the long-term benefit of EVAR is less well
established. Although previous studies suggest a potential
survival benefit free of cardiac events for patients under-
going EVAR, these patients are still considered to be at















Fig 2. Long-term survival is shown of patients with an estimated
glomerular filtration rate60mL/min/1.73m2with andwithout
asymptomatic perioperative troponin release.
Fig 3. Long-term survival is shown in statin users and nonusers
after endovascular abdominal aortic aneurysm repair.population.The compromised long-term survival of EVAR patients
might be explained by the high prevalence of symptomatic
and asymptomatic underlying coronary artery disease. As
was already shown 25 years ago by Hertzer et al,11 only 6%
of patients with an AAA have a healthy coronary artery tree,
and 36% have severe coronary artery disease. More recent
series using functional tests such as dobutamine stress echo-
cardiography confirmed these findings. As has been shown
previously, the presence and extent of coronary artery dis-
ease seems to have much greater effect on long-term sur-
vival of patients with AAA than the choice of treatment.6
The finding of cardiac troponin T in approximately 10%
of patients undergoing EVAR is in line with previously
published work. In a previous smaller study, we found a
10.2% incidence of perioperative myocardial injury after
EVAR in 49 unselected patients.12 Also in 55 EVAR pa-
tients at high clinical cardiac risk according to traditional
cardiac risk factors, the incidence of perioperative myocar-
dial injury was 13%, which is relatively low.7 Other authors
confirmed these findings. Abraham et al1 found an inci-
dence of 10% in patients undergoing elective EVAR. It is
remarkable that none of these patients had clinical signs of
ischemia and would thus have been missed if routine car-
diac troponin T measurement had not been performed.
These findings agree with the results of the current study, as
77% of patients with troponin release were asymptomatic.
The concealed cardiac damage might also explain the
low incidence of ischemic cardiac complications reported in
other studies and randomized trials. For example, the
DREAM trial showed a 5.3% incidence of cardiac compli-
cations in the endovascular group, of which 66% were
classified as being not severe.13 Patients undergoing EVAR
are usually hospitalized for only 2 or 3 days postoperatively;
thus, it might be argued that the true incidence of myocar-
dial damage is even higher than reported in the current
study because troponin levels were only measured during
hospitalization.
Cardiac troponin release occurs in almost 100% of
patients with an acute coronary syndrome as a consequence
of the ischemic cardiac event.8 Indeed, troponin I and T are
cardiac isoforms and solely expressed in cardiac muscles,
making them very sensitive markers for myocardial injury.
Several other conditions can trigger troponin release, how-
ever, including sepsis, systemic inflammatory response syn-
drome, pulmonary embolism, acute and chronic heart fail-
ure, and end-stage renal disease.8 The cause of troponin
release in these conditions is not clarified. A transient
leakage of troponin of the cytosolic pool might be an
explanation for troponin release into the bloodstream, in
particular, in case of pulmonary embolism or after physical
exercise.
The current study supports the observations in patients
undergoing major open vascular surgery. In a study of 447
patients by Landesberg et al,14 even minor elevations of
cardiac troponin during the first 3 days postoperatively
were associated with a twofold increased risk for long-term
mortality after major vascular surgery. A study by Kertai et
al15 including 393 patients undergoing open aortic or
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creased risk for patients with asymptomatic troponin re-
lease. A study by de Virgilio et al16 of patients undergoing
EVAR with an asymptomatic rise in creatine kinase-MB
fraction or troponin found a clear trend for an increased risk
for long-term mortality (P  .09). An important note to
their study is that it began in 1996, when troponin essays
were less sensitive. This is reflected in the 6% incidence of
patients with troponin release in their study compared with
11% in our study.
Patients with renal dysfunction who undergo EVAR
repair are considered to be at high risk for long-term events.
In a study by Azizzadeh et al17 in 398 patients, a reduced
GFR was associated with a significantly increased risk for
long-term mortality. The meaning of troponin release in
patients with renal dysfunction is a matter of recurrent
debate. Patients with end-stage renal disease often have
levels of troponin 99th percentile.
In the current study, patients with renal dysfunction
more frequently had postoperative asymptomatic troponin
release; for these patients, the pattern of troponin release is
of particular interest. Patients with renal dysfunction might
have elevated troponin levels before the actual cardiac
damage occurs; therefore, in the presence of a classic pro-
nounced rise and fall of troponin levels in these patients,
they still should be considered as having a cardiac event.18
The current study showed that new-onset perioperative
troponin release in patients with moderate renal dysfunc-
tion (eGFR 60 mL/min/1.73 m2) is associated with a
poor long-term prognosis. Therefore, asymptomatic
perioperative troponin release in patients with renal dys-
function should not be considered a relatively harmless
condition.
The optimal treatment of patients with asymptomatic
troponin release is still ill defined. As with all vascular surgical
patients, statins and aspirin should be prescribed.19,20 In the
nonoperative setting, patients with non-ST elevation myo-
cardial infarctions are usually prescribed aggressive anti-
platelet therapy, such as clopidogrel.21 Whether it would
also improve long-term outcome in patients with margin-
ally elevated levels of troponin T after EVAR remains to be
determined.
The true incidence of myocardial damage may be even
higher than reported in the current study because troponin
was only measured during hospitalization, and many pa-
tients are discharged3 days postoperatively. In fact, in the
current study the median length of stay was 3 days; thus,
some patients might have had troponin release after post-
operative day 3 that was missed.
CONCLUSIONS
Perioperative asymptomatic troponin T release in pa-
tients undergoing EVAR is a marker for poor long-term
survival, even in those with renal dysfunction. Although
only 10% of patients experience asymptomatic troponin T
release, 55% of deaths during 2.9 years of follow-up oc-
curred in this group of patients. Stringent follow-up andadherence to secondary prevention guidelines in these pa-
tients is of utmost importance.
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Dr W. Moore (Los Angeles, Calif): How do we know that, in
fact, that there has been myocardial damage just because you
happen to have an asymptomatic troponin release in the absence of
EKG changes?
Our cardiologists often describe the so called troponin leak
phenomenon, particularly when there may be an episode of hyper-
tension in the perioperative interval. I think your increased inci-
dence of mortality may simply represent a higher risk group in
which the troponin leak population occurred. You showed that
there was a higher incidence of prior myocardial infarction and
other comorbidities in the troponin leak group. Therefore I won-
der if the troponin event is simply a marker for the higher risk
group rather than a morbid event in of itself?
Dr Schouten: As shown on the slides on pathophysiology of
troponin release, there must be a compromised membrane of the
cardiomyocytes for troponin to be released into the bloodstream.
This implies that there must be cardiac damage one way or the
other.
We also did a subgroup analysis for patients who stayed at the
ICU for at least two days after surgery, more or less the critically ill
patients with episodes of hypotension, and also, in that group of
patients, those with troponin release did much worse than patients
without troponin release. While the exact pathophysiology is not
entirely clear for this group of patients, the main message is that if
you have a patient with cardiac troponin release, either it’s symp-
tomatic or asymptomatic, they do much worse on the long term.
These patients probably will benefit from more aggressive medical
therapy and more aggressive follow-up on the long term.
Dr J. Ricotta (Washington, DC): I was actually going to ask
you to elaborate on that last question. In your units, do you have a
protocol for how you evaluate these patients after you find that
they have asymptomatic troponin release. Do you have a standard
algorithm for evaluation and management?
Dr Schouten: Currently we are performing another study in
this patient population with asymptomatic cardiac troponin T
release. It’s called the DECREASE VII trial. And what we do in
that trial is that we randomize patients who have asymptomatic
cardiac troponin release to receive either clopidogrel on top of beta
blockers, statins and aspirin, or placebo on top of this medication.
In terms of cardiac stress testing or coronary angiography, it
depends on whether or not the patient will get eventually EKGEKG abnormalities, we will not perform any other additional
cardiac evaluation or cardiac tests.
Dr P.Goodney (Lebanon, NH): We studied similar questions
in our vascular study group in Northern New England. One of the
questions we struggled with was a lack of a multivariate finding for
beta blockers and statins. I noticed your model similarly didn’t
include those medical regimens. I thought you might comment on
that.
Dr Schouten: At our unit all patients are on beta blockers, so
it is impossible to find any benefit or harm of beta blockers in this
study. What we have found in this study in terms of medication
use—I did not include it in this presentation because of time
restraints is that patients who were not on statins, which were
approximately 30% of the patients, had a worse outcome than
patients on statins. The odds ratio was approximately 0.65. So
statins seem to work. But on the other hand, nowadays, all our
patients will get statins anyway.
Dr P. Gloviczki (Rochester, Minn): Have you looked at
preoperative cardiac variables, cardiac risk factors, and would they
predict your elevated troponin release?
Dr Schouten: One of the slides showed a multivariate analysis
for predictors of asymptomatic cardiac troponin release, and these
risk factors were more or less the same as for more hard endpoints
like myocardial infarction and cardiac deaths.
Dr F. Mussa (New York, NY): Along the same line of Dr.
Gloviczki’s question, did you go back and change your preopera-
tive workup for those patients based on your troponin release?
Nowadays, we’re doing less extensive workup for patients with
stable coronary disease undergoing vascular or endovascular pro-
cedures.
Dr Schouten: No, we did not change our preoperative
workup based on these study results. Our current preoperative
policy is based on earlier DECREASE studies, and in particular
DECREASE II: patients with 1 risk factor can undergo surgery
quite safely with beta blockers and statins. Also patients with 2 risk
factors will benefit from statins and beta blockers and can undergo
vascular surgery quite safely.
The problem is with patients who have 3 or more risk factors.
In those patients we perform cardiac stress testing, in all patients.
But that’s not something that we’ve investigated in this study and
it’s not something which we will change based on these study
results.
